top of page
Aro-Biotherapeutics-About-Us-Banner-2.jp
Dark%20blue%20gradeint%20overlay_edited.

Scientific Publications & Presenations

2022 TIDES USA Conference

Centyrin-targeted siRNA conjugates demonstrate potential new therapeutic approach for reduction of skeletal muscle glycogen in Pompe disease

Authors: Aro Biotherapeutics

View Presenation
2022 ELRIG Conference

Creating A New Class of Centyrin - Oligonucleotide Therapeutics

Authors: Aro Biotherapeutics

View Presenation
2022 3rd RNAi-Based Therapeutics Summit

Creating a New Class of Receptor Targeted Genetic Medicines

Authors: Aro Biotherapeutics

View Presentation
2022 Muscular Dystrophy Association Conference Poster

Extra-hepatic delivery of Centyrin-targeted oligonucleotides

Authors: Rebecca Meyer

View Poster
2021 Oligonucleotides Therapeutics Society Meeting

Creating a New Class of Receptor Targeted Genetic Medicines

Authors: Aro Biotherapeutics

View Poster
2021 Molecular Therapy Publication

Centyrin ligands for extrahepatic delivery of siRNA

Authors: Donna Klein, Shalom Goldberg, Christopher S. Theile, Richard Dambra, Kathleen Haskell, Elise Kuhar, Tricia Lin, Rubina Parmar, Muthiah Manoharan, Mark Richter, Meizhen Wu, Jeannine Mendrola Zarazowski, Vasant Jadhav, Martin A. Maier, Laura Sepp-Lorenzino, Karyn O’Neil, and Vadim Dudkin

View Article
2020 RAS Europe Poster Presentation

Bispecific Centyrin – panKRAS siRNA conjugate with anti-proliferative activity in KRAS mutant tumor cell lines

Authors: Robert Kolakowski, Russell C. Addis, Swapnil Kulkarni, Joshua Gorsky, Rebecca Meyer, Yao Xin, Evana Mortezavi, Evan Greenawalt, Karyn T. O’Neil, Steven G. Nadler

View Poster
2020 AACR Poster Presentation

Tumor-targeted knockdown of KRAS mutants with novel Centyrin: siRNA conjugates

Authors: Robert Kolakowski, Russell C. Addis, Swapnil Kulkarni, Joshua Gorsky, Rebecca Meyer, Yao Xin, Evana Mortezavi, Evan Greenawalt, Karyn T. O’Neil, Steven G. Nadler

View Poster
2020 Oligonucleotide Society 2020 meeting

Tumor Targeted Knockdown of KRAS mutants with novel Centyrin: siRNA conjugates

Authors: Robert Kolakowski, Russell C. Addis, Swapnil Kulkarni, Joshua Gorsky, Rebecca Meyer, Yao Xin, Evana Mortezavi, Evan Greenawalt, Karyn T. O’Neil, Steven G. Nadler

View Poster
2019 AACR Poster Presentation

ABX9xx: A multi-specific Centyrin that synergizes to attenuate intracellular signaling in cMET/EGFR positive tumor cells

Authors: Russ Addis, Robert Kolakowski, Swapnil Kulkarni, Josh Gorsky, Rebecca Meyer, Yao Xin, Steve Nadler, Karyn O’Neil

View Poster
2017 Bioconjugate Chemistry

Evaluation of a Centyrin-Based Near-Infrared Probe for Fluorescence-Guided Surgery of Epidermal Growth Factor Receptor Positive Tumors

Authors: Sakkarapalayam M. Mahalingam, Vadim Y. Dudkin, Shalom Goldberg, Donna Klein, Fang Yi, Sunil Singhal, Karyn T. O’Neil and Philip S. Low

View Article
2016 Protein Engineering, Design & Selection

Engineering a targeted delivery platform using Centyrins

Authors: Shalom D. Goldberg, Rosa M.F. Cardoso, Tricia Lin, Tracy Spinka-Doms, Donna Klein, Steven A. Jacobs, Vadim Dudkin, Gary Gilliland and Karyn T. O’Neil

View Article
2014 Protein Engineering, Design & Selection

Selection of high-affinity Centyrin FN3 domains from a simple library diversified at a combination of strand and loop position

Authors: Michael D. Diem, Linus Hyun, Fang Yi, Randi Hippensteel, Elise Kuhar, Cassandra Lowenstein, Edward J. Swift, Karyn T. O’Neil and Steven A. Jacobs

View Article
2012 Protein Engineering, Design & Selection

Design of novel FN3 domains with high stability by a consensus sequence approach

Authors: Steven A.Jacobs, Michael D. Diem, Jinquan Luo, Alexey Teplyakov, Galina Obmolova, Thomas Malia, Gary L. Gilliland and Karyn T. O’Neil

View Article
bottom of page